TBC1D22B

Across TCGA pan-cancer cohorts, TBC1D22B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TBC1D22B data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TBC1D22B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TBC1D22B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where TBC1D22B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.979	0.314	.005	40	view →
PDAC	DFS	Tertile	II,III,IV	0.679	0.969	.002	22	view →
LUAD	DFS	Median	All	0.851	0.947	.001	6	view →
OV	DFS	Median	All	0.657	1.000	.043	4	view →
HNSC	DFS	Quartile	II,III,IV	0.988	0.840	.015	2	view →
LSCC	OS	Tertile	III,IV	0.868	0.510	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TBC1D22B–CCRCC (DFS)

Open the CCRCC breakdown →